Population Pharmacokinetic Study of Colistin in Patients Infected With Multiresistant Gram-negative Bacteria

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (918 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: majorpatientspriorage 18hcv
  Phrases that lowered it: the pharmacokineticspharmacokinetics ofinhaledpharmacokineticantibiotics
• Sponsor's past termination rate: 42.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Primary purpose: not given (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Drug's FAERS reports with a death: 25% (raises risk) · Drug's FDA history
• Responsible party: not given (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Design: not given (raises risk) · Design
• Drug's FAERS reports marked serious: 91.0% (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Blinding: not given (lowers risk) · Design
• Sponsor's past trials: 7 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: not given (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients NCT02408185 · started 2011 · scored riskier than 41% of active trials completed
• Population Pharmacokinetic (PK) Study of Zinforo (Ceftaroline) in Critical Care Patients With Early-onset Pneumonia and Normal or Augmented Renal Clearance NCT03025841 · started 2016 · scored riskier than 46% of active trials completed
• Nebulized and Intravenous Colistin in Ventilator Associated-pneumonia NCT02906722 · started 2017 · scored riskier than 79% of active trials terminated
• Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity NCT06650384 · started 2024 · scored riskier than 11% of active trials completed
• Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure NCT02142075 · started 2014 · scored riskier than 50% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.